Besides, DNMT inhibitor (DNMTi) 5‐Aza‐2′‐deoxycytidine (5‐Aza‐CdR) has been employed, both in solitary and in synergism with chemotherapies, in pre‐clinical and clinical trials in urological malignancy setup, such as bladder cancer, prostate cancer and testicular cancer, in addition to their approved ground in treatment of hematological malignancies.39 This evidence concerns the gene DNMT1 and prostate carcinoma.